Marksans Pharma Q4 Results
- BSE: 524404
- NSE: MARKSANS
- ISIN: INE750C01026
- Sector: Biotechnology & Drugs
BSE
174.70
0.70 (0.40%)
0.70 (0.40%)Volume20.30 K
Updated: Wed 11 Mar, 2026 | 15:29:42
NSE
172.95
-1.11 (-0.64%)
-1.11 (-0.64%)Volume3.68 L
Updated: Wed 11 Mar, 2026 | 15:47:21
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q4 Results Highlights
Quarter ended Mar 25
Note: Comparison is on QoQ basis
Quarterly - Marksans Pharma Q4 Results
*All figures in crores except per share values
| Fiscal Period | Mar 25 | Dec 25 | QoQ Comp | Mar 24 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 605.45 | 618.01 | 7.39% | 471.43 | 28.43% |
| Depreciation/ Amortization | 22.74 | 24.33 | 9.94% | 21.06 | 8.02% |
| Operating Income | 103.01 | 136.42 | -12.76% | 88.58 | 16.28% |
| Net Income | 90.54 | 113.20 | -13.41% | 78.29 | 15.65% |
| Other Operating Expenses Total | 160.27 | 165.47 | 2.67% | 100.80 | 59.00% |
| Net Income Before Taxes | 116.09 | 150.62 | -18.96% | 100.27 | 15.78% |
| Total Revenue | 708.46 | 754.43 | 3.90% | 560.01 | 26.51% |
| Selling/ General/ Admin Expenses Total | 97.22 | 111.99 | 9.92% | 79.75 | 21.91% |
| Diluted Normalized EPS | 2.00 | 2.50 | -13.50% | 1.73 | 15.34% |